Collaborations, contracts and licensing agreements (Tables)

3 Months Ended

Mar. 31, 2026

Revenue from Contract with Customer [Abstract]

Summary of collaborations

Revenues are summarized in the following table:

	Three Months Ended March 31,
	2026		2025
	(in thousands)
Revenue from collaborations and licenses
Acuitas Therapeutics, Inc.	$	204	$	504
Qilu Pharmaceutical Co., Ltd.	—		812
License revenue from Genevant	178,741		—
Non-cash royalty revenue
Alnylam Pharmaceuticals, Inc.	181		448
Total revenue	$	179,126	$	1,764